Šalis: Kanada
kalba: anglų
Šaltinis: Health Canada
LIDOCAINE HYDROCHLORIDE
ASTRAZENECA CANADA INC
N01BB02
LIDOCAINE
5MG
LIQUID
LIDOCAINE HYDROCHLORIDE 5MG
BLOCK/INFILTRATION
50 ML
Ethical
LOCAL ANESTHETICS
Active ingredient group (AIG) number: 0101280003; AHFS:
CANCELLED POST MARKET
2015-05-31
COPYRIGHT 1954-2015 ASTRAZENECA CANADA INC. Page 1 of 31 PRESCRIBING INFORMATION XYLOCAINE ® PARENTERAL SOLUTIONS Lidocaine Hydrochloride Injection USP 0.5% lidocaine hydrochloride (5 mg/mL) 1% lidocaine hydrochloride (10 mg/mL) 2% lidocaine hydrochloride (20 mg/mL) Lidocaine Hydrochloride and Epinephrine Bitartrate Injection USP 1% lidocaine hydrochloride (10 mg/mL) with 1:200,000 epinephrine (0.005 mg/mL) 1% lidocaine hydrochloride (10 mg/mL) with 1:100,000 epinephrine (0.010 mg/mL) 2% lidocaine hydrochloride (20 mg/mL) with 1:200,000 epinephrine (0.005 mg/mL) Local Anesthetic AstraZeneca Canada Inc. 1004 Middlegate Road Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Date of Revision: February 23, 2015 Submission Control No: 176093 XYLOCAINE ® is a registered trademark of the AstraZeneca group of companies. COPYRIGHT 1954-2015 ASTRAZENECA CANADA INC. Page 2 of 31 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ...................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................... 5 ADVERSE REACTIONS ............................................................................................... 12 DRUG INTERACTIONS ............................................................................................... 14 DOSAGE AND ADMINISTRATION ........................................................................... 16 OVERDOSAGE .............................................................................................................. 20 ACTION AND CLINICAL PHARMACOLOGY .......................................................... 22 STORAGE AND STABILITY .................................... Perskaitykite visą dokumentą